Navigation Links
Monoclonal Antibody Induces Death in Liver Cancer Cells

Researchers at the University of Pittsburgh School of Medicine have found that a newly available monoclonal antibody has the potential to induce death in liver cancer cells.

In a study, the monoclonal antibodies' use demonstrated significantly reduces tumour cell proliferation and survival in human and mouse hepotocellular cancer (HCC) cell lines.

The researchers say that the new findings have significant implications not only for the treatment of live cancer, but also for various other types of cancer-skin cancer, brain tumours, gastrointestinal tumours, prostate tumours, ovarian cancer and leukaemia.

According to the background information in an article published in the journal published in Molecular Cancer Therapeutics, most cases of HCC are secondary to either a viral hepatitis infection or cirrhosis of the liver.

Despite recent advances, it remains a disease of grim prognosis due to the poorly understood mechanism of how the disease originates and spreads. Most patients live only a short time after diagnosis.

Dr. Satdarshan P. Singh Monga, Associate Professor in the division of cellular and molecular pathology at the university, directed his colleagues to obtain rat and human liver cancer cell lines so as to analysed the cell lines for the levels of expression of an receptor tyrosine kinase (RTK) protein, shown to be highly active in the liver of HCC patients in some previous studies, known as platelet-derived growth factor receptor-alpha (PDGFRa).

The researchers also analysed the cells for their level of activation of the PDGFRa gene.

It was found that at an early foetal stage of liver development in the mouse, the level of expression of PDGFRa was 37 times higher compared to later stages of development in the adult mouse liver. The researchers also found significantly higher levels of PDGFRa in rat and human liver cancer cell lines as compared to normal ce lls in culture.

When both human and mouse live cancer cell lines were treated with a monoclonal antibody, tumour cell proliferation significantly decreased and programmed cell death (apoptosis) increased four to 18 fold, as compared to normal control cells.

The researchers say that the results depict PDGFRa as a possible new therapeutic target for the treatment of HCC.

"We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work. We now have identified a pathway that appears to be overly active in more than 70 per cent of the cancers we examined and, when targeted, leads to significant reduction in tumour cell proliferation and survival," said Dr. Monga.

He also says that targeting the PDGFRa pathway in liver cancer cells does not affect normal liver cells, making the treatment relatively non-toxic.

"Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease," he added.


'"/>




Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
4. Monoclonal Antibody based system for Anthrax detection
5. Monoclonal Antibody Reduces Exacerbations in Asthmatics
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. A New Monoclonal Antibody Kills Cancer Cells
8. Human Antibody That Can Block SARS
9. Cuba Registers New Antibody
10. Single Sugar Enables Antibody to Treat Inflammation
11. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
Breaking Medicine Technology: